{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:22Z","timestamp":1782918022895,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Given the substantial disease burden, appropriate and effective management of migraine is a public health priority. To gain insights into real-world migraine management practices in Taiwan, current treatment patterns, costs, and health care resource use were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, longitudinal study using the Taiwan National Health Insurance Research Database. Included patients had an initial diagnosis of migraine (defined using International Classification of Diseases codes) between 1 January 2013 and 31 December 2017. Data analyzed included demographics; the use, number, and type of acute and preventive medications; and drug and medical services costs. Data were stratified according to migraine type (chronic [CM] or episodic [EM] migraine).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 312,718 patients were included in the analyses: 53,992 (17.3%) had CM and 258,726 (82.7%) had EM. Most patients (81.7%) had used acute and\/or preventive medications; acute medications used more frequently than preventive medications (78.0% vs. 20.2%). Acute medications were used by 81.6 and 77.3% of patients with CM and EM, respectively. Commonly used acute medications were acetaminophen (68.8%), ergots (49.4%), and non-steroidal anti-inflammatory drugs (38.4%); the use of triptans (6.0%), tramadol (3.1%), and other opioids (0.2%) was less common. A total of 28.6 and 18.5% of patients with CM and EM, respectively, used preventive medications. Flunarizine (68.9%), propranolol (40.7%), and topiramate (16.0%) were the most commonly used preventive medications. Most patients had used 1\u20132 acute or preventive medications, with the use of \u22653 acute or preventive medications more common in patients with CM than EM. Average total medical cost<jats:italic>per annum<\/jats:italic>was 4,169 New Taiwan Dollars (NTDs) per CM patient and 2,928 NTDs per EM patient, with CM patients having higher costs associated with medical service utilization and acute medication use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These real-world data suggest unmet needs for Taiwanese patients with migraine, including under-utilization of preventive medications and greater costs and health care resource use for patients with CM versus EM. These findings provide important information on treatment patterns, cost, and health care resource use for patients with migraine in Taiwan.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1222912","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:44:31Z","timestamp":1692269071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment pattern and health care resource utilization for Taiwanese patients with migraine: a population-based study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yen-Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Tai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Chang","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Fong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Panni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Dell\u2019Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: will health politicians now take notice?","volume":"19","author":"Steiner","year":"2018","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/head.12328","article-title":"Epidemiology of headache disorders in the Asia-pacific region","volume":"54","author":"Peng","year":"2014","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1468-2982.2000.00085.x","article-title":"Prevalence of migraine in Taipei, Taiwan: a population-based survey","volume":"20","author":"Wang","year":"2000","journal-title":"Cephalalgia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/0333102412468668","article-title":"Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan","volume":"33","author":"Wang","year":"2013","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s0929-6646(09)60151-0","article-title":"Validity, reliability and application of the Taiwan version of the migraine disability assessment questionnaire","volume":"105","author":"Hung","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10194-012-0447-4","article-title":"Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan","volume":"13","author":"Chen","year":"2012","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s1726-4901(08)70078-9","article-title":"Impact of migraine on the employed labor force in Taiwan","volume":"71","author":"Fuh","year":"2008","journal-title":"J Chin Med Assoc"},{"key":"ref11","first-page":"89","article-title":"Treatment Guideline Subcommittee of the Taiwan Headache Society 2022 Taiwan guidelines for acute treatment of migraine","volume":"31","author":"Lau","year":"2022","journal-title":"Acta Neurol Taiwan"},{"key":"ref12","first-page":"164","article-title":"Treatment Guideline Subcommittee of the Taiwan Headache Society 2022 Taiwan guidelines for preventive treatment of migraine","volume":"31","author":"Wu","year":"2022","journal-title":"Acta Neurol Taiwan"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1080\/03007995.2020.1815181","article-title":"Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine","volume":"36","author":"Yang","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","article-title":"Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention","volume":"176","author":"Schoenen","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months","volume":"22","author":"Caronna","year":"2021","journal-title":"J Headache Pain"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.96.15_supplement.1514","article-title":"Characterizing preventive treatment gaps in migraine: results from the CaMEO study (1514)","volume":"96","author":"Nahas","year":"2021","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10194-020-01154-x","article-title":"Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis","volume":"21","author":"Roessler","year":"2020","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","article-title":"Poor medical care for people with migraine in Europe \u2013 evidence from the Eurolight study","volume":"19","author":"Katsarava","year":"2018","journal-title":"J Headache Pain"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","article-title":"Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","article-title":"Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and care of MigrainE (OVERCOME [Japan]) study","volume":"37","author":"Hirata","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref22","first-page":"33","article-title":"Treatment Guideline Subcommittee of the Taiwan Headache Society. Medical treatment guidelines for preventive treatment of migraine","volume":"26","author":"Huang","year":"2017","journal-title":"Acta Neurol Taiwan"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine \u2013 revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1526-4610.1993.hed3306335.x","article-title":"Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine","volume":"33","author":"Lamsudin","year":"1993","journal-title":"Headache"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1468-2982.1996.1605328.x","article-title":"Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine","volume":"16","author":"Verspeelt","year":"1996","journal-title":"Cephalalgia"},{"key":"ref26","first-page":"267","article-title":"Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial","volume":"12","author":"Mitsikostas","year":"1997","journal-title":"Funct Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1017\/S0317167100041962","article-title":"Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine","volume":"19","author":"Gawel","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1526-4610.1991.hed3110650.x","article-title":"Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability","volume":"31","author":"Sorensen","year":"1991","journal-title":"Headache"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1526-4637.2011.01295.x","article-title":"A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis","volume":"13","author":"Luo","year":"2012","journal-title":"Pain Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ane.12626","article-title":"Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial","volume":"135","author":"Lai","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"ref31","article-title":"Propranolol","volume-title":"StatPearls [internet]","author":"Shahrokhi","year":"2022"},{"key":"ref32","year":"2022"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-021-01336-1","article-title":"Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study","volume":"22","author":"MaassenVanDenBrink","year":"2021","journal-title":"J Headache Pain"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","article-title":"Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study","volume":"93","author":"Ferrari","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14737175.2021.1842733","article-title":"Triptanophobia in migraine: a case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients","volume":"21","author":"Mart\u00ednez-P\u00edas","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.14018","article-title":"Burden of increasing opioid use in the treatment of migraine: results from the migraine in America symptoms and treatment study","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1526-4610.2011.02050.x","article-title":"Opioid use and dependence among persons with migraine: results of the AMPP study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11916-016-0581-9","article-title":"Opioid treatment of migraine: risk factors and behavioral issues","volume":"20","author":"Stone","year":"2016","journal-title":"Curr Pain Headache Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pain.2009.01.013","article-title":"Excessive opioid use and the development of chronic migraine","volume":"142","author":"Bigal","year":"2009","journal-title":"Pain"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-021-01224-8","article-title":"Medication overuse and drug addiction: a narrative review from addiction perspective","volume":"22","author":"Takahashi","year":"2021","journal-title":"J Headache Pain"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/JCMA.0000000000000720","article-title":"Prevalence of opioid prescriptions in Taiwan (2008-2018)","volume":"85","author":"Wang","year":"2022","journal-title":"J Chin Med Assoc"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/head.13543","article-title":"Episodic and chronic migraine in primary care","volume":"59","author":"Young","year":"2019","journal-title":"Headache"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.14247","article-title":"Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans","volume":"62","author":"Shao","year":"2022","journal-title":"Headache"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1222912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T05:36:22Z","timestamp":1702964182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1222912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":43,"alternative-id":["10.3389\/fneur.2023.1222912"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1222912","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"article-number":"1222912"}}